HKEX Review of the Risk of Technological Obsolescence for an Applicant's Key Products

The Hong Kong Stock Exchange (HKEX) has intensified its scrutiny of technological obsolescence risk for listing applicants, a trend that accelerated following a series of high-profile post-IPO performance failures in the biotech and hardware sectors during 2023-2024. The Listing Division’s December 2024 guidance note on viability assessments explicitly directs sponsors to stress-test an applicant’s core product lifecycle against a five-year horizon, a shift from the previous three-year standard. This recalibration reflects the Exchange’s concern that rapid technological substitution—particularly in semiconductor, renewable energy, and AI-driven medical devices—can render a company’s primary revenue stream obsolete before its first annual report is filed. For sponsors and legal advisers structuring a Main Board or GEM application, the burden of proof has moved from demonstrating current commercial traction to proving sustained technological defensibility. Failure to adequately address this risk in the prospectus can trigger a return of the application under HKEX Listing Rule 9.03(3), as observed in at least four unpublished rejections in the first half of 2025.

The Regulatory Framework for Technological Obsolescence Assessment

Listing Rule 9.03(3) and the Suitability Requirement

HKEX Listing Rule 9.03(3) empowers the Exchange to reject an application if the issuer or its business is not suitable for listing. The Exchange has increasingly interpreted “suitability” to encompass the long-term viability of an applicant’s core technology. In a series of Listing Decisions from 2023 to 2025 (notably LD127-2023 and LD14-2025), the Listing Division clarified that an applicant whose primary product relies on a technology facing imminent substitution by a superior alternative may be deemed unsuitable, regardless of current revenue levels. The Exchange’s stated rationale is that a listing is a public market privilege, not a right, and that investors must be protected from companies whose business model lacks a demonstrable technological moat.

The practical implication for applicants is that the prospectus must include a dedicated risk factor section, typically drafted under SFC Code of Conduct paragraph 5.2, that quantifies the probability and potential revenue impact of technological obsolescence within the next three to five years. This goes beyond generic boilerplate language; the Exchange expects specific competitor benchmarking, patent expiration timelines, and R&D pipeline milestones. For example, an applicant in the lithium-ion battery space must address the emergence of solid-state alternatives, citing published research from institutions like the University of Oxford or Tsinghua University, and provide a credible timeline for when its current chemistry will be commercially displaced.

The Five-Year Horizon Shift

The December 2024 guidance note from the Listing Division represents a material tightening of the assessment window. Previously, the Exchange accepted a three-year forward-looking analysis for technology risk, consistent with the typical business plan horizon in a prospectus. The extension to five years directly addresses the observation that many technology-driven companies, particularly in the pre-revenue biotech sector under Chapter 18A, experienced product obsolescence within 36 months of listing. Data from the HKEX’s own 2024 Market Statistics Report indicates that 22% of 18A-listed companies had to materially revise their primary product strategy within three years of their IPO, a figure the Exchange considers unacceptable.

Sponsors must now commission independent technology assessments from qualified third-party experts, such as engineering consultancies or academic institutions, and include these reports as exhibits to the listing application. The cost and timeline implications are significant: a full technology obsolescence audit can take 8-12 weeks and cost between HKD 1.5 million and HKD 3 million, depending on the sector. For a pre-IPO company with limited cash reserves, this represents a non-trivial financial hurdle that must be factored into the listing timeline.

Sector-Specific Applications of the Technology Obsolescence Review

Semiconductor and Advanced Manufacturing

The semiconductor sector has been the primary focus of the Exchange’s enhanced scrutiny, driven by the rapid pace of process node advancement and geopolitical supply chain shifts. An applicant manufacturing legacy 28nm or 40nm chips must demonstrate that its customer base is not solely dependent on applications where these nodes will be obsolete within five years. The Exchange, in a March 2025 consultation paper (HKEX-CP2025-02), specifically flagged the risk of Chinese domestic semiconductor companies that rely on design IP licensed from US or European firms subject to export controls. If the license is non-renewable or subject to revocation, the applicant’s technology stack is inherently compromised.

Sponsors are now expected to include a legal opinion from a qualified PRC law firm (e.g., JunHe, King & Wood) on the enforceability and duration of technology licensing agreements, with particular attention to the PRC Technology Import and Export Regulations (2022 revision). The Exchange’s Listing Division has also requested, in at least two recent cases, a detailed mapping of the applicant’s supply chain for critical components, showing alternative sourcing options in the event of a technology embargo. This level of granularity was previously reserved for national security reviews under HKEX Listing Rule 8.04, but is now standard for any semiconductor applicant.

Biotech and Medical Devices

For biotech applicants under Chapter 18A or 18C, the technology obsolescence risk is often tied to patent cliffs and the emergence of next-generation therapies. The Exchange’s 2024 review of 18A companies found that 15% of applicants had their primary drug candidate’s mechanism of action superseded by a competing therapy during the listing process itself. The Listing Division now requires a detailed patent landscape analysis, including freedom-to-operate opinions from a qualified patent firm, and a clear articulation of the applicant’s second-generation pipeline.

The specific concern is for applicants developing monoclonal antibodies or CAR-T therapies where the target antigen is also being pursued by multiple competitors. In a notable 2025 rejection, the Exchange deemed a CAR-T applicant unsuitable because its target (CD19) faced imminent substitution by bispecific T-cell engagers (BiTEs) with superior safety profiles, as demonstrated in Phase II trial data published by Amgen in January 2025. The sponsor’s failure to address this substitution risk in the prospectus was the stated reason for the application’s return under Rule 9.03(3).

Renewable Energy and Clean Technology

The clean technology sector presents a unique challenge because the pace of technological change is driven by government policy as much as by market forces. The Exchange’s Listing Division has issued specific guidance (LD15-2025) for applicants in the solar photovoltaic and wind turbine manufacturing space. The key risk is that a technology standard—such as PERC solar cells versus TOPCon or HJT—can be rendered obsolete by a single policy shift in a major market like the PRC or the European Union.

Applicants must now include a scenario analysis showing the financial impact if their primary technology is excluded from a key feed-in tariff or subsidy program within the next five years. The Exchange expects this analysis to be based on published policy roadmaps from the PRC National Energy Administration and the European Commission’s Renewable Energy Directive. For example, a manufacturer of fixed-tilt solar trackers must demonstrate that its product can be adapted to bifacial module requirements, which are becoming the default standard in utility-scale projects. Failure to do so can result in a suitability finding, as occurred with one applicant in Q1 2025.

Practical Implications for Sponsors and Legal Advisers

Enhanced Due Diligence Requirements

The technological obsolescence review has fundamentally altered the due diligence scope for a listing application. Sponsors must now engage technical experts at the outset of the engagement, not as an afterthought. The typical timeline for a Main Board application has extended by 4-6 weeks to accommodate the technology audit, and the cost has increased by an estimated 10-15% for the sponsor’s fees alone. The SFC’s Code of Conduct paragraph 17.6, which requires sponsors to exercise reasonable due diligence, is now interpreted to include a specific obligation to verify the applicant’s claims about technological superiority.

Legal advisers must draft the prospectus risk factors with a level of specificity that would have been unusual two years ago. Generic statements such as “the company’s technology may become obsolete” are no longer sufficient. The Exchange expects a quantified probability assessment, preferably with a range of outcomes (e.g., a 20-30% probability that the applicant’s primary product will face material obsolescence within five years, resulting in a 40-60% revenue decline). This requires close coordination between the sponsor’s financial due diligence team, the technical experts, and the legal team.

The Role of the Independent Technical Expert

The independent technical expert’s report has become a critical document in the listing application. The expert must be a recognized authority in the relevant field, with no prior commercial relationship with the applicant. The Exchange has rejected reports from experts who were previously engaged by the applicant for consulting work, citing a conflict of interest under SFC Code of Conduct paragraph 5.4. The report must cover at least the following areas: (1) a description of the current technology landscape, (2) a forward-looking assessment of competing technologies, (3) a timeline for potential substitution, (4) an analysis of the applicant’s R&D pipeline and its ability to pivot, and (5) a conclusion on the applicant’s technological defensibility.

The expert’s conclusion is not binding on the Exchange, but a negative or qualified opinion will almost certainly trigger a return of the application. In practice, sponsors are now conducting a pre-engagement screening of potential experts to ensure their views align with the applicant’s narrative. This has created a market for expert reports that are independent in form but aligned in substance, a tension that the SFC has flagged as a potential area for future enforcement action.

Actionable Takeaways for Listing Applicants

• Engage a qualified independent technical expert at the pre-application stage (at least six months before the intended A1 filing) to conduct a technology obsolescence audit and incorporate its findings into the business plan.
• Include in the prospectus a quantified scenario analysis showing the revenue impact of technological substitution over a five-year horizon, with specific references to competitor products and published research.
• For applicants in regulated sectors (semiconductor, biotech, clean energy), obtain legal opinions on the enforceability of technology licenses and the stability of government policy frameworks that support the applicant’s primary technology.
• Ensure the sponsor’s due diligence work program explicitly addresses technological obsolescence risk, with documented verification of the applicant’s claims about its products’ lifecycle and competitive position.
• Prepare a second-generation pipeline or product diversification strategy that can be presented to the Exchange as evidence of the applicant’s ability to adapt if its primary technology becomes obsolete.